GLP-1 medicines in kidney and liver inflammation Treatment with an exenatide analog was found to significantly decrease hepatic lipid accumulation, liver weight, and plasma levels of alanine transaminase in mice on a high-trans-fat diet
As additional FDA submissions and real-world studies emerge, further clarification of optimal dosing strategies and sustained efficacy will shape its role in future metabolic treatment protocols
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
Some patients carry genetic variants in the GLP1R gene (such as rs6923761) that naturally reduce receptor sensitivity, making them reach a plateau sooner than others
Regulatory agencies have investigated this concern for GLP-1 agonists as a class
A encrenca da vez envolve a circulao nas redes sociais de anncios vendendo retatrutida , um medicamento experimental, que ainda no foi lanado
